Does HBV, HCV Coinfection Up NHL Risk in ART-Treated HIV?
(HealthDay News) — Chronic coinfection with hepatitis B virus (HBV) and hepatitis C virus (HCV) is associated with non-Hodgkin's lymphoma (NHL) among patients with HIV receiving antiretroviral treatment (ART), according to a study published online Oct. 18 in the Annals of Internal Medicine.
Qing Wang, Ph.D., from the University Hospital Basel in Switzerland, and colleagues conducted a cohort study to examine whether chronic HBV and HCV infection correlate with increased incidence of NHL in HIV-infected patients using data from 18 of 33 cohorts from the Collaboration of Observational HIV Epidemiological Research Europe. Data were included for 52,479 treatment-naive patients (2.6 and 14.3 percent with chronic HBV infection and HCV infection, respectively); 77 percent of these patients started ART.
The researchers found that 252 treatment-naive and 310 treated patients developed NHL (incidence rates of 219 and 168 per 100,000 person-years, respectively). The hazard ratios for NHL were 1.33 (95 percent confidence interval [CI], 0.69 to 2.56) for HBV infection and 0.67 (95 percent CI, 0.40 to 1.12) for HCV infection in treatment-naive patients, and 1.74 (95 percent CI, 1.08 to 2.82) and 1.73 (95 percent CI, 1.21 to 2.46), respectively, for treated patients.
"In HIV-infected patients receiving ART, chronic coinfection with HBV and HCV is associated with an increased risk for NHL," the authors write.
Several authors disclosed financial ties to the biopharmaceutical industry.